众生药业(002317.SZ)：公司的昂拉地韦颗粒III期临床试验正在积极推进中

Group 1 - The core viewpoint of the article is that Zhongsheng Pharmaceutical is actively advancing the Phase III clinical trial of its drug, Anglatide granules (research code: ZSP1273) [1] Group 2 - The company has communicated this progress through its investor interaction platform [1]